152 related articles for article (PubMed ID: 36481298)
1. Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
Ohte N; Tanaka A; Kitada S; Yamada T; Eguchi K; Teragawa H; Takeishi Y; Kodama K; Seo Y; Node K;
J Cardiol; 2023 Jun; 81(6):508-512. PubMed ID: 36481298
[TBL] [Abstract][Full Text] [Related]
2. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
3. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
Tanaka A; Hisauchi I; Taguchi I; Sezai A; Toyoda S; Tomiyama H; Sata M; Ueda S; Oyama JI; Kitakaze M; Murohara T; Node K;
ESC Heart Fail; 2020 Aug; 7(4):1585-1594. PubMed ID: 32349193
[TBL] [Abstract][Full Text] [Related]
4. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between NT-proBNP Levels and Left Ventricular Ejection Fraction in Patients with Unstable Angina and Diabetes Mellitus and Preserved LVEF.
Gao X; Liu R; Wang P; Wang W; Zhao HQ
Int Heart J; 2022; 63(5):821-827. PubMed ID: 36184543
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
7. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
9. Analysis of combined detection of N-terminal pro-B-type natriuretic peptide and left ventricular ejection fraction in heart function in patients with acute CO poisoning.
Liu SD; Shen Q; Lv C; Zhang P; Yu H; Yang L; Wu L
Am J Emerg Med; 2014 Oct; 32(10):1212-4. PubMed ID: 25151325
[TBL] [Abstract][Full Text] [Related]
10. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial.
de la Espriella R; Wahlberg KJ; Infeld M; Palau P; Núñez E; Sanchis J; Meyer M; Núñez J
Eur J Heart Fail; 2024 Jan; 26(1):167-176. PubMed ID: 38124404
[TBL] [Abstract][Full Text] [Related]
11. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
12. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
[TBL] [Abstract][Full Text] [Related]
13. Amino-terminal pro-brain natriuretic peptid in prediction of left ventricular ejection fraction.
Bajrić M; Baraković F; Kusljugić Z; Salkić N; Jahić E; Ascerić M; Ljuca F; Mrsić D; Smajić E; Caluk J; Hajrić R
Bosn J Basic Med Sci; 2008 Aug; 8(3):282-6. PubMed ID: 18816264
[TBL] [Abstract][Full Text] [Related]
14. Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.
Dencker M; Stagmo M; Dorkhan M
Vasc Health Risk Manag; 2010 Jun; 6():373-82. PubMed ID: 20539839
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
16. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
18. The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle.
Kirillova VV; Sokolova LA; Meshchaninov VN; Pershanova VI
Ter Arkh; 2018 Sep; 90(9):68-72. PubMed ID: 30701738
[TBL] [Abstract][Full Text] [Related]
19. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
[TBL] [Abstract][Full Text] [Related]
20. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
